There’s a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid — a claim the French company disputes.
Continue reading Sanofi Denies Offering $69-$80 Price Range to Genzyme
Sanofi Denies Offering $69-$80 Price Range to Genzyme originally appeared on DailyFinance on Fri, 08 Oct 2010 08:30:00.
Filed Under: Company News, Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Stocks in the News